1. Overview
  2. All Stocks
  3. Zomedica Corp.

Zomedica (ZOMDF.US) – Strong Sell: Rating and Stock Analysis 2026/2027

0.08
Analysis framework by , founder of TradeDesk · Data: EODHD, insider trades from SEC Form 4 filings · Updated
Share this analysis:

No analysts currently cover Zomedica with a public price target. We add the price target automatically as soon as at least one analyst publishes a rating. Until then, use the technical analysis and the key figures below.

About Zomedica – Medical Devices

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. It offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. The company provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, Assisi EquiLoop, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan. Read more about the company

Key Figures for Zomedica

$78.4M Market cap
$36.9M Revenue
Medical Devices Industry
- P/E
2.13 P/S
0.71 P/B
United States Listed on exchange
zomedica.com Website
Healthcare Sector

What kind of stock is Zomedica?

Speculative stock

Zomedica is classified as a speculative stock.

Score Overview for Zomedica

💰 Value Score 45/100 (Neutral)
⭐ Quality Score 7/100 (Very Low)
🚀 Momentum Score 18/100 (Very Low)
📊 Total Score 23/100

⚠️ 3 red flags identified 1 critical

Our analysis has identified 3 potential risk factors in Zomedica that investors should be aware of.

⚠️ Weak financial health: The Piotroski score is only 3/9 – the company shows signs of weakened profitability, liquidity or capital structure.
🚨 Negative profit margin: The profit margin is -51.4% – the company is losing money on its operations.
⚠️ Negative return on equity: ROE is -16.3% – the company is generating a negative return for shareholders.

📈 Valuation

The P/S ratio is 2.1. The P/B ratio is 0.7, below book value, which can point to a value opportunity.

🏦 Financial Health

The Piotroski score is 3 out of 9 — weak financial health, be careful. Altman Z2 is 3.32 (healthy balance sheet — low risk). The debt-to-equity ratio (D/E) is 6.0% — low debt, a solid balance sheet.

🚀 Momentum & Short Interest

Short interest is 4.71%.

↑ Back to navigation

Zomedica Short Selling 2026: 4.7% Sold Short

Moderate short interest: 4.7% of the free float
Short % of free float
4.7%
Assessment
Moderate short interest
Short squeeze risk
Low
Data source
EODHD
Reported about twice a month
The stock has a moderate share of short selling. Between 2-5% of the freely traded shares are sold short, which is within the normal range for most stocks.

Short interest comes from our data provider EODHD. The figure is reported about twice a month; we check it every trading day.
Short Interest Scale
0% 2% 5% 10% 20%+
Low Moderate High Very High Extreme
▲
4.7%

↑ Back to navigation

When Does Zomedica Report Earnings?

The next earnings date for Zomedica is not yet available. Check the company's investor calendar for more information.



↑ Back to navigation

Technical Analysis of Zomedica 2026 – Signal: Strong Sell

Overall Technical Signal: Strong Sell

Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated October 7, 2026.

Trend Analysis of Zomedica Corp.

Zomedica Corp. is in a short-term uptrend. The price of $0.08 is 0.1% above the 20-day average ($0.08). Medium term, the picture is negative: the price is 3.5% below the 50-day average ($0.08). Long term, the stock is 23.9% below the 200-day average ($0.10), which signals a long-term downtrend.

Death Cross: The 50-day average (0.08) is below the 200-day average (0.10), which is a classic bearish signal for Zomedica Corp..

Is Zomedica Corp. overbought or oversold?

Zomedica Corp. has an RSI of 48.7, right in the middle of the neutral zone. There is no clear buying or selling pressure.

MACD Analysis for Zomedica Corp.

Daily MACD: MACD is negative (-0.001), which means the short-term trend is bearish (the 12-day EMA is below the 26-day EMA). MACD is below the signal line (-0.001) by 0.000, which confirms growing negative momentum in the downtrend.

Weekly MACD: MACD5 is negative (-0.007), which indicates a broader bearish long-term trend. MACD5 is below the signal line (-0.006) by 0.001, which confirms continued negative long-term momentum.

Overall MACD assessment: Both the daily and weekly MACD are negative and below their signal lines. Trend and momentum are negative across time horizons – the strongest bearish signal.

Risk Profile for Zomedica Corp.

Zomedica Corp. has an annual standard deviation of 70.3%, which classifies the stock as Extremely speculative. Only risk-tolerant investors should consider this stock, because the price swings can be very large.

Overall Technical Conclusion for Zomedica Corp.

Trend: Negative. The price trades below SMA50 and SMA200.

MACD trend (zero line): Daily bearish (-0.001). Weekly bearish (-0.007).

MACD momentum (signal): Daily falling. Weekly falling.

RSI: 48.7 – neutral.

Technical signal: Strong Sell

The price is in a downtrend (below SMA50/SMA200) and MACD is negative on both a daily and weekly basis. Avoid buying and consider closing existing positions.

↑ Back to navigation

Frequently Asked Questions About Zomedica stock in 2026

Should you buy Zomedica stock now?
No, the technical signal for Zomedica is currently Strong Sell. Zomedica trades at $0.08 as of Oct 7, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -0.001 with falling momentum (signal: -0.001); RSI is at 48.7 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average). The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Zomedica stock?
There is currently no active analyst price target for Zomedica.
Is Zomedica a dividend stock?
No, Zomedica does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Zomedica stock?
Zomedica is rated as a stock in the risk category Extremely speculative. the annual standard deviation is 70.3%, which classifies the stock as Extremely speculative.
Is Zomedica overvalued?
Zomedica has the following valuation ratios: a P/S ratio of 2.1, a P/B ratio of 0.7.
Is Zomedica overbought?
No, Zomedica is not overbought. RSI is at 48.7 (neutral zone). The technical indicators show: RSI is at 48.7 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 0.1% above the 20-day average (short-term uptrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Zomedica earnings report?
The date of the next earnings report for Zomedica has not been published yet. Check the company's investor calendar for updates.
Is Zomedica shorted?
Yes, Zomedica is shorted with 4.7% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Zomedica stock?
There is currently no registered insider trading for Zomedica.
Is Zomedica a good stock?
Based on our total score, Zomedica is rated as a poor stock with a total score of 23 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 45/100, Quality: 7/100, Momentum: 18/100. In addition: technical signal: Strong Sell. Whether Zomedica is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Zomedica stock?
The outlook for Zomedica based on current data: the stock is in a downtrend (below SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Zomedica stock moving?
Zomedica is stable right now. The technical indicators show: the price is close to the 20-day average. For the latest context, see our technical analysis and insider section above.
How high can Zomedica go?
There is currently no active analyst price target for Zomedica. The stock has traded between $0.06 and $0.16 over the last 52 weeks. The price is 50.6% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Zomedica fall?
The stock has traded as low as $0.06 over the last 52 weeks — that is 24.1% below the current price of $0.08. The biggest decline (drawdown) in the same period was 62.5% from high to low. Within a year, the price typically swings about ±70.3% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Zomedica do?
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. It offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy... The company belongs to the Healthcare sector, more specifically the Medical Devices industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Zomedica as an investment.
Did Zomedica raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Zomedica. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Zomedica making money or losing money?
No, Zomedica is currently not making money — the company is losing money with a negative profit margin of -51.4%, a substantial loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Zomedica go bankrupt?
The bankruptcy risk of Zomedica is rated as low. Altman Z2 (a model for assessing financial distress) is 3.32 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 3 — which is weak. Debt relative to equity is 6% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Zomedica have a lot of debt?
No, Zomedica has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 6%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
↑ Back to navigation

Other Stocks in Healthcare

Compare Zomedica with other stocks in the healthcare sector. Click a stock to see its technical analysis, insider trading and key figures.

See all 106 stocks in the Healthcare sector

Explore More